BioCentury | Jan 8, 2021
Management Tracks

Moderna hires chief commercial officer as it ramps up COVID vaccine rollout; plus MorphoSys, Silence, Verastem, Viking, Destiny and Allen Institute

...CMO. He was VP, head of oncology clinical research, clinical research development at bluebird bio Inc. (NASDAQ:BLUE).Silence Therapeutics plc...
...arrives, at which time he will join the board and become president-emeritus. BC Staff Moderna Inc. MorphoSys AG Allen Institute Silence Therapeutics plc Verastem...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Blocking PCSK9 alone or with anti-PD-1 therapies for cancer

...established cardiovascular disease.Leqvio inclisiran, an siRNA against PCSK9 from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Novartis AG (NYSE:NVS; SIX:NOVN) and Silence Therapeutics plc...
BioCentury | Nov 5, 2020
Management Tracks

Rosén joins Horizon as CSO and R&D head; plus moves at Boehringer, Dr. Reddy’s, Mylan and more

...CTO. He worked with the cancer and endocrine/metabolic company on a consultancy basis for the past year.siRNA play Silence Therapeutics plc (NASDAQ:SLN...
...Aspen Neuroscience Inc. and Gossamer Bio Inc. (NASDAQ:GOSS). Danielle Golovin GlaxoSmithKline plc Dr. Reddy's Laboratories Ltd. Mylan N.V. Rhythm Pharmaceuticals Inc. Silence Therapeutics plc Monte...
BioCentury | Oct 12, 2020
Management Tracks

Rivera joins Akili as CMO; plus moves at Polyneuron, Checkmate, CytomX, BIO, ProQR, Silence and OncoSec

...head of global research and development and CSO at Santen Inc. CFO Rob Quinn will leave Silence Therapeutics plc...
BioCentury | Sep 16, 2020
Management Tracks

O’Brien to lead Tizona in wake of Gilead deal; plus Silence, PacBio, Rhythm

...post at Trishula Therapeutics last month (see “Gilead Places Latest Bet on Cancer Immunosuppression”).siRNA company Silence Therapeutics plc...
...as chief commercial officer and head of international for the past two years. Jeff Cranmer Tizona Therapeutics Inc. Silence Therapeutics plc Rhythm...
BioCentury | Aug 26, 2020
Deals

Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues

...programs for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy.London-based Silence Therapeutics plc...
...growth factor β 3VEGF – Vascular endothelial growth factor BC Staff AVID200 Takeda Pharmaceutical Co. Ltd. Blackstone Group BeiGene Ltd. Prelude Therapeutics Inc. Silence Therapeutics plc Sirnaomics...
BioCentury | May 28, 2020
Finance

May 27 Quick Takes: Atara raises $176M on back of MS data; plus Exscientia’s $60M C round, Geron, Silence, Arvelle, ViaCyte, Poxel, Accure, Tollys

...The cancer company lost $0.25 (14%) to $1.59 on Tuesday. Silence planning NASDAQ listing London-based Silence Therapeutics plc...
...to this report. Targets TLR3 - Toll-like receptor 3 Robin Sawka, Staff Writer Robin Sawka, BioCentury Staff Geron Corp. Silence Therapeutics plc Arvelle...
BioCentury | Mar 25, 2020
Deals

AstraZeneca, Silence partner to bring siRNA therapies to extrahepatic tissues

...in RNA therapeutics as the company establishes its foothold in the modality through external innovation. Silence Therapeutics...
...cardiovascular and rare disease indications. Targets VEGF-A - Vascular endothelial growth factor A Lauren Martz, Senior Editor Silence Therapeutics plc [MERGED]...
BioCentury | Feb 15, 2020
Management Tracks

Immunomedics names Itri CMO; plus Hua, GenMark, AAM, Vividion, Sophia Genetics, Enterprise, Encoded, Palleon and more

...Ltd. appointed David Horn Solomon as chairman, succeeding Gaby Salem. Horn Solomon was CEO at Silence Therapeutics plc...
BioCentury | Aug 6, 2019
Company News

Management tracks: Allogene snags Adaptimmune's Amado; plus Foundation Medicine, CymaBay and more

...and CFO. He was SVP and CFO of Agile Therapeutics Inc. (NASDAQ:AGRX). RNA therapy company Silence Therapeutics plc...
...become president of the liposome delivery company. Jonathan Block, Associate Editor Allogene Therapeutics Inc. CymaBay Therapeutics Inc. LipoMedix Pharmaceutical Inc. Silence Therapeutics plc Aprea...
Items per page:
1 - 10 of 253
BioCentury | Jan 8, 2021
Management Tracks

Moderna hires chief commercial officer as it ramps up COVID vaccine rollout; plus MorphoSys, Silence, Verastem, Viking, Destiny and Allen Institute

...CMO. He was VP, head of oncology clinical research, clinical research development at bluebird bio Inc. (NASDAQ:BLUE).Silence Therapeutics plc...
...arrives, at which time he will join the board and become president-emeritus. BC Staff Moderna Inc. MorphoSys AG Allen Institute Silence Therapeutics plc Verastem...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Blocking PCSK9 alone or with anti-PD-1 therapies for cancer

...established cardiovascular disease.Leqvio inclisiran, an siRNA against PCSK9 from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Novartis AG (NYSE:NVS; SIX:NOVN) and Silence Therapeutics plc...
BioCentury | Nov 5, 2020
Management Tracks

Rosén joins Horizon as CSO and R&D head; plus moves at Boehringer, Dr. Reddy’s, Mylan and more

...CTO. He worked with the cancer and endocrine/metabolic company on a consultancy basis for the past year.siRNA play Silence Therapeutics plc (NASDAQ:SLN...
...Aspen Neuroscience Inc. and Gossamer Bio Inc. (NASDAQ:GOSS). Danielle Golovin GlaxoSmithKline plc Dr. Reddy's Laboratories Ltd. Mylan N.V. Rhythm Pharmaceuticals Inc. Silence Therapeutics plc Monte...
BioCentury | Oct 12, 2020
Management Tracks

Rivera joins Akili as CMO; plus moves at Polyneuron, Checkmate, CytomX, BIO, ProQR, Silence and OncoSec

...head of global research and development and CSO at Santen Inc. CFO Rob Quinn will leave Silence Therapeutics plc...
BioCentury | Sep 16, 2020
Management Tracks

O’Brien to lead Tizona in wake of Gilead deal; plus Silence, PacBio, Rhythm

...post at Trishula Therapeutics last month (see “Gilead Places Latest Bet on Cancer Immunosuppression”).siRNA company Silence Therapeutics plc...
...as chief commercial officer and head of international for the past two years. Jeff Cranmer Tizona Therapeutics Inc. Silence Therapeutics plc Rhythm...
BioCentury | Aug 26, 2020
Deals

Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues

...programs for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy.London-based Silence Therapeutics plc...
...growth factor β 3VEGF – Vascular endothelial growth factor BC Staff AVID200 Takeda Pharmaceutical Co. Ltd. Blackstone Group BeiGene Ltd. Prelude Therapeutics Inc. Silence Therapeutics plc Sirnaomics...
BioCentury | May 28, 2020
Finance

May 27 Quick Takes: Atara raises $176M on back of MS data; plus Exscientia’s $60M C round, Geron, Silence, Arvelle, ViaCyte, Poxel, Accure, Tollys

...The cancer company lost $0.25 (14%) to $1.59 on Tuesday. Silence planning NASDAQ listing London-based Silence Therapeutics plc...
...to this report. Targets TLR3 - Toll-like receptor 3 Robin Sawka, Staff Writer Robin Sawka, BioCentury Staff Geron Corp. Silence Therapeutics plc Arvelle...
BioCentury | Mar 25, 2020
Deals

AstraZeneca, Silence partner to bring siRNA therapies to extrahepatic tissues

...in RNA therapeutics as the company establishes its foothold in the modality through external innovation. Silence Therapeutics...
...cardiovascular and rare disease indications. Targets VEGF-A - Vascular endothelial growth factor A Lauren Martz, Senior Editor Silence Therapeutics plc [MERGED]...
BioCentury | Feb 15, 2020
Management Tracks

Immunomedics names Itri CMO; plus Hua, GenMark, AAM, Vividion, Sophia Genetics, Enterprise, Encoded, Palleon and more

...Ltd. appointed David Horn Solomon as chairman, succeeding Gaby Salem. Horn Solomon was CEO at Silence Therapeutics plc...
BioCentury | Aug 6, 2019
Company News

Management tracks: Allogene snags Adaptimmune's Amado; plus Foundation Medicine, CymaBay and more

...and CFO. He was SVP and CFO of Agile Therapeutics Inc. (NASDAQ:AGRX). RNA therapy company Silence Therapeutics plc...
...become president of the liposome delivery company. Jonathan Block, Associate Editor Allogene Therapeutics Inc. CymaBay Therapeutics Inc. LipoMedix Pharmaceutical Inc. Silence Therapeutics plc Aprea...
Items per page:
1 - 10 of 253